Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saikosaponin b2 (SSb2) is a triterpenoid saponin naturally occurring in the roots of *Bupleurum* species, commonly known as Radix Bupleuri in traditional Chinese medicine. It is being investigated primarily for its antineoplastic and antiviral properties. In oncology research, SSb2 has demonstrated the ability to inhibit the proliferation and migration of breast cancer cells (such as the MCF-7 line) by downregulating the **STAT3 signaling pathway**. This downregulation leads to decreased expression of **vasodilator-stimulated phosphoprotein (VASP)** and matrix metallopeptidases **MMP2** and **MMP9**, which are critical for tumor cell invasion and metastasis. Additionally, SSb2 is recognized for its potent antiviral activity, particularly against the **Hepatitis C virus (HCV)** and certain coronaviruses, where it acts by interfering with early stages of the viral life cycle, including attachment and entry into host cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saikosaponin b2.